105 related articles for article (PubMed ID: 19032230)
1. Health economics of asthma: assessing the value of asthma interventions.
Campbell JD; Spackman DE; Sullivan SD
Allergy; 2008 Dec; 63(12):1581-92. PubMed ID: 19032230
[TBL] [Abstract][Full Text] [Related]
2. Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?
Kim CH; Dilokthornsakul P; Campbell JD; van Boven JFM
J Allergy Clin Immunol Pract; 2018; 6(2):619-632. PubMed ID: 28967548
[TBL] [Abstract][Full Text] [Related]
3. Development of an economic model to assess the cost effectiveness of asthma management strategies.
Price MJ; Briggs AH
Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.
McQueen RB; Sheehan DN; Whittington MD; van Boven JFM; Campbell JD
Pharmacoeconomics; 2018 Aug; 36(8):957-971. PubMed ID: 29736895
[TBL] [Abstract][Full Text] [Related]
5. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
Dal Negro RW; Tognella S; Pradelli L
J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
Faria R; McKenna C; Palmer S
Value Health; 2014 Dec; 17(8):772-82. PubMed ID: 25498772
[TBL] [Abstract][Full Text] [Related]
7. Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care.
Honkoop PJ; Loijmans RJ; Termeer EH; Snoeck-Stroband JB; van den Hout WB; Bakker MJ; Assendelft WJ; ter Riet G; Sterk PJ; Schermer TR; Sont JK;
J Allergy Clin Immunol; 2015 Mar; 135(3):682-8.e11. PubMed ID: 25174865
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of first-line controller therapies for persistent asthma.
Shih YC; Mauskopf J; Borker R
Pharmacoeconomics; 2007; 25(7):577-90. PubMed ID: 17610338
[TBL] [Abstract][Full Text] [Related]
9. Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial.
Baxter-Jones AD; Helms PJ; Russell G; Grant A; Ross S; Cairns JA; Ritchie L; Taylor R; Reid DM; Osman LM; Robins S; Fletcher ME
Health Technol Assess; 2000; 4(28):1-89. PubMed ID: 11074396
[TBL] [Abstract][Full Text] [Related]
10. Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma.
Lamb HM; Culy CR; Faulds D
Pharmacoeconomics; 2000 Nov; 18(5):487-510. PubMed ID: 11151402
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions.
Ehteshami-Afshar S; Zafari Z; Hamidi N; FitzGerald JM; Lynd L; Sadatsafavi M
Value Health; 2019 Sep; 22(9):1070-1082. PubMed ID: 31511184
[TBL] [Abstract][Full Text] [Related]
12. Database studies in asthma pharmacoeconomics: uses, limitations and quality markers.
Thomas M; Cleland J; Price D
Expert Opin Pharmacother; 2003 Mar; 4(3):351-8. PubMed ID: 12614187
[TBL] [Abstract][Full Text] [Related]
13. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study.
Zafari Z; Lynd LD; FitzGerald JM; Sadatsafavi M
J Allergy Clin Immunol; 2014 Oct; 134(4):908-915.e3. PubMed ID: 24875619
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of guideline advice for children with asthma: a literature review.
Feenstra TL; Rutten-Van Mölken MP; Jager JC; Van Essen-Zandvliet LE
Pediatr Pulmonol; 2002 Dec; 34(6):442-54. PubMed ID: 12422342
[TBL] [Abstract][Full Text] [Related]
15. An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice.
Goossens LM; Riemersma RA; Postma DS; van der Molen T; Rutten-van Mölken MP
Adv Ther; 2009 Sep; 26(9):872-85. PubMed ID: 19768640
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
Sullivan SD; Turk F
Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
[TBL] [Abstract][Full Text] [Related]
17. Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial.
De Vera MA; Sadatsafavi M; Tsao NW; Lynd LD; Lester R; Gastonguay L; Galo J; FitzGerald JM; Brasher P; Marra CA
Trials; 2014 Dec; 15():488. PubMed ID: 25494702
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma.
Rodríguez-Martínez CE; Sossa-Briceño MP; Castro-Rodriguez JA
J Asthma; 2013 May; 50(4):410-8. PubMed ID: 23356720
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients.
Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
J Asthma; 2016 Jun; 53(5):538-45. PubMed ID: 26786524
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacoeconomics of asthma].
Jahnz-Rózyk K; Targowski T
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():48-9. PubMed ID: 15524016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
